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ABSTRACT
The herbalist has access to hundreds of years of ob-
servational data on the anticancer activity of many
herbs. Laboratory studies are expanding the clinical
knowledge that is already documented in traditional
texts. The herbs that are traditionally used for anti-
cancer treatment and that are anti-angiogenic through
multiple interdependent processes (including effects
on gene expression, signal processing, and enzyme
activities) include Artemisia annua (Chinese worm-
wood), Viscum album (European mistletoe), Curcuma
longa (curcumin), Scutellaria baicalensis (Chinese
skullcap), resveratrol and proanthocyanidin (grape
seed extract), Magnolia officinalis (Chinese magno-
lia tree), Camellia sinensis (green tea), Ginkgo biloba,
quercetin, Poria cocos, Zingiber officinalis (ginger),
Panax ginseng, Rabdosia rubescens hora (Rabdosia),
and Chinese destagnation herbs. Natural health prod-
ucts target molecular pathways other than angiogen-
esis, including epidermal growth factor receptor, the
HER2/neu gene, the cyclo-oxygenase-2 enzyme, the
nuclear factor kappa-B transcription factor, the pro-
tein kinases, the Bcl-2 protein, and coagulation path-
ways. Quality assurance of appropriate extracts is
essential prior to embarking upon clinical trials. More
data are required on dose–response, appropriate com-
binations, and potential toxicities. Given the multiple
effects of these agents, their future use for cancer
therapy probably lies in synergistic combinations.
During active cancer therapy they should generally
be evaluated in combination with chemotherapy and
radiation. In this role, they act as modifiers of bio-
logic response or as adaptogens, potentially enhanc-
ing the efficacy of the conventional therapies or
reducing toxicity. Their effectiveness may be in-
creased when multiple agents are used in optimal
combinations. New designs for trials to demonstrate
activity in human subjects are required. Although
controlled trials may be preferable, smaller studies
with appropriate endpoints and surrogate markers for
anti-angiogenic response could help to prioritize
agents for larger, resource-intensive phase III trials.
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1. INTRODUCTION
The biochemical signalling pathways of angiogen-
esis form a complex, interconnected web. Inhibition
of one part of the web may result in compensation
through another pathway. Because botanicals con-
tain a variety of organic chemical complexes, they
usually act on multiple targets. A potential advan-
tage of phytochemicals is that they may act through
multiple pathways and reduce the development of
resistance by cancer cells. This model of pharmacog-
nosy recognizes the advantage of administering the
whole plant product to maximize activity. Over-ex-
traction of a specific chemical constituent may re-
move this therapeutic gain. The challenge for modern
pharmacognosy is to ensure that the optimum mix-
ture of chemical constituents is maintained when a
product is purified. Usually, such assurance will re-
quire a combination of chemical and biologic assays.
The additional anticancer properties of some anti-
angiogenic botanicals are briefly discussed here. Their
properties may affect various biochemical pathways
that indirectly influence angiogenesis. Traditional
practice has been to combine multiple natural health
products, and scientifically, such combination may
provide a therapeutic advantage.
2. MULTISTEP ACTIVITY OF
PHYTOCHEMICAL COMPLEXES DERIVED
FROM HERBS
2.1 Targeting Alternative Angiogenesis Pathways
The adipocytokines—polypeptides produced by
adipocytes—have autocrine, paracrine, and endocrine
activities, and are associated with obesity,
hyperinsulinemia, and chronic vascular disease as100
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well as with the development of cancer 1. The
adipocytokines include vascular endothelial growth
factor (VEGF), hepatocyte growth factor (HGF), leptin,
tumour necrosis factor alpha (TNFa), heparin-bind-
ing epidermal growth factor, insulin-like growth fac-
tor, and interleukin-6 (IL-6). All can promote
angiogenesis.
Curcumin (from turmeric) and epigallocatechin-
3 gallate (EGCG, from green tea) can inhibit aminopep-
tidase-N (CD13), a member of the matrix
metalloproteinase family that is implicated in the
angiogenic switch process 2–4. Curcumin and EGCG can
also interfere with the expression of VEGF by suppress-
ing a series of activities that promote angiogenesis.
These angiogenic pathways include production of
transforming growth factor beta (TGFb), amplification
of cyclooxygenase-2 (COX-2) and epidermal growth
factor receptor (EGFR), aberrant expression of src, and
amplification of nuclear factor kappa-B (NF-kB) sig-
nalling. Curcumin, grape seed extract, and green tea
constituents may also interfere with endothelial cell
function by inhibiting the engagement of specific
integrins 5,6. These phytochemicals interact at mul-
tiple levels to suppress the inflammatory, hyperpro-
liferative and transformative processes that constitute
carcinogenesis.
2.2 Targeting EGFR (HER1)
In many human tumours, EGFR is overexpressed. Such
overexpression is associated with more aggressive
disease, relative resistance to cytotoxic chemotherapy,
and a poorer prognosis. Activity of EGFR induces an-
giogenesis 7. Blockade of EGFR reduces angiogenesis
and cell proliferation 8. Monoclonal antibodies have
been developed to block the receptor or the linked
intracellular signalling system 9–15.
Epidermal growth factor (EGF) stimulates uroki-
nase-type plasminogen activator (uPA) expression,
which can promote angiogenesis. Genistein (an
isoflavone constituent of soy) and curcumin (a con-
stituent of turmeric) both inhibit the effects of EGF 16.
In cell cultures, genistein and curcumin inhibit EGF-
stimulated urokinase production and phosphorylation
of EGFR. Both botanicals also inhibit protein tyrosine
kinases, which could stimulate the enhancement of
uPA levels induced by TGFb 17.
Other natural health products that can block ac-
tivity of EGFR include resveratrol 18 and quercetin 19–21.
2.3 Targeting HER2/neu
The HER2/neu gene (formerly known as c-erbB-2)
is amplified in more than 30% of patients with breast
cancer. It is linked to highly aggressive tumours with
a poorer prognosis. Overexpression of HER2 is also
seen in a significant proportion of patients with other
cancer types, including non-small-cell lung cancer,
ovarian cancer, prostate cancer, and gastric cancer,
in which it may predict a worse outcome 22–26. Am-
plification of the HER2 gene correlates with higher
levels of angiogenesis 27.
Herceptin (Genentech, San Francisco, CA,
U.S.A.) is a drug that inhibits HER2/neu. It is usu-
ally administered adjunctively with cytotoxic chemo-
therapy. The activity of Herceptin may be further
enhanced by oleic acid 28. Emodin, a natural constitu-
ent of Polygonum multiflorum and aloe, inhibits
HER2/neu expression and is toxic against cancer cells,
but nontoxic for normal cells 29.
2.4 Targeting Inflammatory Pathways: COX-2 and
NF-k k k k kB
Prostaglandins are autacoids derived from arachidonic
acid via the COX enzymes. They include prostacyclin,
thromboxane, and prostaglandin E types 1–3. A role
for arachidonic acid–derived prostaglandins in the
process of angiogenesis is now established through in
vitro assays. Prostaglandin E2 is a potent inducer of
angiogenesis. A correlation exists between COX-2 ex-
pression and angiogenesis 30. Neovascularization is
blocked by COX-2 antagonists 31–36.
The COX-2 and lipoxygenase (LOX-5) products of
omega-6 fatty acid metabolism may exert stimula-
tory effects on cancer progression including angio-
genesis. The omega-3 fatty acids and some
pharmacologic inhibitors of eicosanoid biosynthesis
antagonize these effects 37–41. Large amounts of
omega-3 fatty acids [eicosapentaenoic acid (EPA) and
docosahexaenoic acid] are found in cold-water fish
oils. Liquorice contains glycyrrhizic acid and
polyphenols that inhibit COX-2, LOX-5, and protein
kinase C (PKC) and also downregulate EGF 42.
The NF-kB family consists of closely related pro-
tein dimers that bind to a common sequence motif in
DNA called the kB site. The NF-kB inducible transcrip-
tion factor is increased in tissue inflammation, cell
proliferation, and cancers. Nuclear factor kappa B
induces overactivation of the COX enzymes and is
associated with increased angiogenesis 43–46.
The COX enzymes are expressed in most normal
tissues. The COX-1 enzyme synthesizes non-inflam-
matory prostaglandins such as prostaglandin E1. In
contrast, COX-2 is amplified as part of the inflamma-
tory response and produces prostaglandins such as
prostaglandin E2, which may induce uncontrolled cell
proliferation and carcinogenesis.
Nuclear factor kappa B may be amplified by
growth factors, including TGFb and basic fibroblast
growth factor. Besides NF-kB, other transcription fac-
tors, such as activator protein-1 (AP-1) and IL-6, can
stimulate COX-2 transcription. Activator protein-1 also
promotes the metastatic phase of tumour cells.
Angiogenesis mediated by COX-2 also has a role in
the progression of pre-neoplastic lesions to the inva-
sive phenotype 47–50. Conventional cancer therapies—
such as radiation, surgery, and chemotherapy—mayCURRENT ONCOLOGY—VOLUME 13, NUMBER 3
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induce COX-2 amplification as part of the inflammatory
response 51. The significance of this induction is unclear,
but it could hypothetically reduce therapeutic gain.
Several phytochemical derivatives are potent in-
hibitors of NF-kB. These include resveratrol, piceatan-
nol, curcumin, EGCG, 6-gingerol (ginger), ursolic acid
(holy basil), and ginseng 52–56. Many botanical COX-2
inhibiting agents block the amplified activity of the
transcription factor NF-kB without affecting its nor-
mal function.
A variety of natural health products can specifi-
cally inhibit the COX-2 enzyme and could play a role
in reducing tissue toxicity and improving tumour
control when used alongside therapies such as radio-
therapy, chemotherapy, and surgery (Table I) 57. A
botanical that protects an organism from the adverse
effects of an intervention is termed an adaptogen.
Panax ginseng and curcumin are adaptogens that in-
hibit COX-2 and that have anti-angiogenic activity
derived through the inactivation of NF-kB 55,58–61.
2.5 Targeting Protein Kinases
Oncogenes that encode protein kinases may contrib-
ute to the development of cancer. In normal cells,
protein kinases are involved in signals between the
cell membrane and the nucleus, regulating progres-
sion through the cell cycle. Protein kinases control
these processes by activating other messenger pro-
teins that can influence cell proliferation.
Mutated kinase genes have been found in a num-
ber of malignancies, including chronic myelogenous
leukemia and breast and bladder cancers. The mu-
tated kinases can contribute to the development of
cancer. In many tumour cells, protein kinases are
permanently turned on, forcing the cell into constant
division. Examples of abnormal kinases are the abl,
src, and cyclin-dependent kinases. The kinases may
be amplified or permanently switched on by muta-
tions in the control regions of their genes. A com-
monly overproduced kinase in cancer is EGFR.
Numerous phytochemicals are reported to inter-
fere with cell signalling and may reverse the adverse
effects of protein kinase overactivity. Some botani-
cals with COX-2 inhibitory activity target the intracel-
lular signalling molecules 62,63. Inhibition of specific
protein kinases suppresses angiogenesis 64–69.
Carnosol and ursolic acid are compounds found
in Ocimum sanctum (holy basil) and Rosmarinus offi-
cinalis (rosemary) 70. They inhibit the activity of the
tyrosine kinases and ornithine decarboxylase 71.
Carnosol also reduces NF-kB 72 and the anti-apoptotic
protein Bcl-2 73. Genistein and daidzein (isoflavones
found in soy) are specific inhibitors of tyrosine
kinases 74.
Many phytochemicals appear to selectively react
with the regulatory centre of PKC. Curcumin, vitamin E,
green tea (catechins), resveratrol, Ganoderma
lucidum, and liquorice can inhibit PKC activity 42,75–77.
2.6 Targeting the Bcl-2 Protein
The signalling protein Bcl-2 plays a key role in the
process of controlled cell death called apoptosis, which
is necessary to eliminate aged or damaged cells. The
Bcl-2 protein is normally found in the mitochondrial
membrane, where it regulates the release of cyto-
chrome C. The latter protein can trigger a series of
enzymes (caspases) that lead to cell death 78–81. High
Bcl-2 levels are associated with most types of human
cancer and block the release of cytochrome C. They
appear to be a contributor to both inherent and acquired
resistance to anticancer treatments. The BCL2 and
TP53 genes regulate VEGF-mediated angiogenesis 82.
Curcumin and green tea extract inhibit BCL2
expression 83–85. Scutellaria baicalensis contains the
phenolic compounds baicalin, baicalein, wogenin,
and oroxylin. These constituents inhibit BCL2
overexpression, plus COX2 gene expression and NF-
kB activation 86,87. Hibiscus protocatechuic acid is a
phenolic compound isolated from the dried flower of
Hibiscus sabdariffa L.; it inhibits Bcl-2 activity 88,89.
Other inhibitors of Bcl-2 include EPA from fish oil 90,
a lectin extract of Viscum album (mistletoe) 91, 6-
gingerol 92, grape seed extract 93, echinocystic acid
(a triterpene found in ginseng and other Asian
herbs) 94,95, parthenolide (a sesquiterpene lactone
found in feverfew) 96, and beta-lapachone (a quinone
obtained from the bark of the lapacho tree) 97–99.
2.7 Targeting Coagulation Pathways Associated
with Angiogenesis
In some clinical trials, anticoagulation drugs have
been associated with a reduction in metastases 100–102.
TABLE I Natural health products that inhibit cyclo-oxygenase-2
activity 57
Ginger
Aloe vera
EGCG/green tea
Resveratrol
Liquorice
Garlic
Chinese skullcap
Bilberry
Grape seed extract proanthocyanidins
Panax ginseng
Milk thistle
Fish oils: omega-3 fatty acids (eicosapentaenoic acid,
docosahexaenoic acid)
Green-lipped mussel
Antioxidants (vitamins A, C, E; Se, Zn; carotenoids, flavonoids,
coenzyme Q10, N-acetylcysteine, lipoic acid)
Boswellia
Bromelain
Curcumin
Quercetin102
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In Chinese medicine, destagnation herbs are tradi-
tionally thought to overcome blockages of qi and
blood. Laboratory evidence now suggests that these
herbs may have anti-angiogenic and anticoagulation
properties 103–105. A randomized placebo-controlled
trial showed that the addition of “destagnation” herbs
(including Salvia miltiorrhiza and Angelica sinensis)
to radiotherapy doubled both the local control and
the survival rate in patients with nasopharyngeal
cancer 106.
3. CONCLUSION
Angiogenesis involves multiple interdependent pro-
cesses operating at the molecular level. These include
gene expression, signal processing, and enzyme ac-
tivities. Most anti-angiogenic natural health products
block new vessel formation at multiple levels.
Lack of standardization of screening assays may
be an obstacle to defining the most effective prod-
ucts for clinical use. Over-extraction of constituents
may negate some of the potential synergy. Quality
assurance of appropriate extracts is essential before
embarking upon clinical trials.
Most studies of anti-angiogenic activity are based
on in vitro or animal work that cannot be readily ex-
trapolated to humans. Phase I and II studies are re-
quired to determine the potential of these substances
to improve cytotoxic therapies. Mainly preclinical
data exist for most of the naturally derived anti-an-
giogenic agents. However, because anti-angiogenic
agents are mainly cytostatic in nature, the usual para-
digm for anticancer drug development, in which tu-
mour response in phase II trials prompts further
development, is not always appropriate. More data
are required on dose–response, appropriate combi-
nations, and potential toxicities. Given the multiple
effects of these agents, their future use for cancer
therapy probably lies in synergistic combinations.
They may be evaluated alone for the prevention of
cancer recurrence following definitive treatment.
To be suitable for long-term chronic use, these
agents should possess minimal toxicity and should
be orally administered. However, angiogenesis is also
essential for healing of injuries. Most compounds that
inhibit tumour angiogenesis are likely to inhibit physi-
ologic angiogenesis, leading to potential side effects
such as ulceration and bleeding. Studies are required
to determine features that distinguish tumour vessels
from normal vessels so that a therapeutic gain can be
achieved. Some of the differences have already been
described, but the doses and scheduling of anti-an-
giogenic agents appropriate to achieving the optimum
therapeutic gain are unclear.
During active cancer therapy anti-angiogenic
agents should generally be evaluated in combination
with chemotherapy and radiation. In that role, they
act as modifiers of the biologic response and as
adaptogens, potentially enhancing the efficacy and
reducing toxicity of conventional therapies. The com-
bination of diversity in angiogenic factor expression
and different phenotypes of endothelial cells within
various tumours is a major challenge for the devel-
opment of effective anti-angiogenic regimens 107,108.
Effectiveness may be increased when multiple agents
are used in optimal combinations.
Surrogate markers, such as angiogenic cytokines,
are necessary to predict anti-angiogenic response 109.
Circulating levels of fibroblast growth factor–2, VEGF,
vascular cell adhesion molecule–1, endothelial inter-
cellular adhesion molecule–1, insulin-like growth
factor–1, and cytokines such as interleukin-8 may
correlate with tumour angiogenesis 110–114. In addi-
tion, circulating endothelial cells and their progeni-
tors may be a more reliable marker of response to
anti-angiogenic therapies 115,116. Non-invasive func-
tional imaging, such as positron emission tomogra-
phy and functional magnetic resonance imaging, may
play a role 117.
Current laboratory evidence suggests a useful role
for natural health products in the treatment of cancer.
The input of an herbalist, an oncologist, a laboratory
scientist, and a clinical trials methodologist to the
research effort is essential to distil the wealth of tra-
ditional knowledge into a modern framework that can
be evaluated scientifically. Information on traditional
dose levels is important for designing initial phase I
clinical trials for safety and maximum tolerated dose
(Table II). However, the traditional model of phar-
macognosy may not necessarily use the highest dose.
Establishing the maximum tolerated dose in a phase I
study may not always be appropriate. Instead, deter-
mination of the biologically active dose that may
possess less toxicity may be more relevant. Combi-
nations of whole herbs or constituent phytochemicals
at lower doses may be important. In addition, a longer
period of exposure to the natural health product may
be more effective than a short exposure to the high-
est possible dose level. New designs for trials to dem-
onstrate activity in human subjects are required.
Although controlled trials might be preferred,
smaller studies with appropriate endpoints and sur-
rogate markers for anti-angiogenic response could
help to prioritize agents for the larger, resource-in-
tensive phase III trials. Because most of the agents
are expected to be cytostatic, it is inappropriate to
require the standard criteria of measured tumour re-
sponse. On the other hand, simply confirming stable
disease may be misleading. More research on surro-
gate markers of anti-angiogenic response is obviously
necessary before resources can be directed to large-
scale clinical trials (Table III).
The further development of natural health prod-
ucts for clinical trials will require a team effort be-
tween academic centres, government, and industry.
Appropriate financial support and market protection
will be necessary to encourage this activity. New ways
of supporting evidence-based innovation for naturalCURRENT ONCOLOGY—VOLUME 13, NUMBER 3
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health products are necessary, without necessarily
separating and isolating all the constituents of a natu-
ral health product simply to allow patent registration.
Commercial protection for companies that provide
quality assurance and clinical trials evidence may be
necessary. Another model includes government sup-
port for evaluation, with some profit being returned
to the government when a product is commercial-
ized. Part of the funding for clinical studies of the
AE-941 shark cartilage derivative (Neovastat: Æterna
Zentaris, Quebec, QC, Canada) came from Technol-
ogy Partnerships Canada, a research support program
of the federal government of Canada 118.
Teamwork between the oncologist, the herbalist,
the laboratory scientist, and the research methodolo-
gist is important for studying anti-angiogenic herbs
and other natural health products. As clinical trials
introduce these products into the clinic, more defini-
tive evidence of efficacy will be provided and more
cancer patients may potentially experience improved
outcomes.
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